Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC

Welcome to OncLive On Air^®! I’m your host today, Caroline Seymour.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. 

In today’s episode, sponsored by Bristol Myers Squibb, we had the pleasure of speaking with Martin Dietrich, MD, PhD, an assistant professor of internal medicine at the University of Central Florida, a fellow of the American College of Physicians, and a medical oncologist at Florida Cancer Specialists & Research Institute, to discuss recent advances and ongoing research in stage III non–small cell lung cancer (NSCLC).

In our exclusive interview, Dietrich discussed the latest developments with immunotherapy and targeted therapy in stage III NSCLC.

Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. 

OncLive^® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive^® and OncLive^® State of the Science Summit and follow our OncLive^® page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.